Literature DB >> 28594717

Long-term Risk of Urinary Adverse Events in Curatively Treated Patients With Rectal Cancer: A Population-Based Analysis.

Mary R Kwaan1, Yunhua Fan, Stephanie Jarosek, Sean P Elliott.   

Abstract

BACKGROUND: Treatment modalities for rectal cancer, including radiation, are associated with urinary adverse effects.
OBJECTIVE: The purpose of this study was to determine the influence of surgery and radiation therapy for rectal cancer on long-term urinary complications.
DESIGN: Using the Surveillance Epidemiology and End Results-Medicare data set from the United States, patients with rectal cancer older than 66 years of age who underwent rectal resection between 1992 and 2007 were stratified into treatment groups that accounted for surgical resection and the timing of radiation therapy, if used. A control group of patients who did not have rectal cancer were matched by age, sex, demographics, and comorbidities. The primary outcome was a urinary adverse event defined as a relevant urinary diagnosis with an associated procedure. Patients with rectal cancer in different treatment groups were compared with control patients using a propensity-adjusted, multivariable Cox regression analysis. SETTINGS: The study was conducted with the Surveillance Epidemiology and End Results-Medicare data set from the United States at our institution.
RESULTS: Of the 11,068 patients with rectal cancer, 56.2% had surgical resection alone, 21.7% received preoperative radiation, and 22.1% received postoperative radiation. The median follow-up for all of the groups of patients was >2 years. All of the groups of patients with rectal cancer were more likely to develop a urinary adverse event compared with control subjects. Adjusted HRs were 2.28 (95% CI, 2.02-2.57) for abdominoperineal resection alone, 2.24 (95% CI, 1.79-2.80) for preoperative radiation and surgical resection, 2.04 (95% CI, 1.70-2.44) for surgical resection and postoperative radiation, and 1.69 (95% CI, 1.52-1.89) for low anterior resection alone. LIMITATIONS: Treatment patterns are somewhat outdated, with a large proportion of patients receiving postoperative radiation. The data did not allow for accurate assessment of urinary tract infections or mild urinary retention that is not managed with a procedure.
CONCLUSIONS: Rectal cancer surgery with or without radiation is associated with a higher risk of urinary complications requiring procedures. Patients who undergo low anterior resection without radiation tend toward the lowest risk for a urinary adverse event.

Entities:  

Mesh:

Year:  2017        PMID: 28594717     DOI: 10.1097/DCR.0000000000000788

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  Early removal of urinary drainage in patients receiving epidural analgesia after colorectal surgery within an ERAS protocol is feasible.

Authors:  André Schreiber; Emine Aydil; Uwe Walschus; Anne Glitsch; Maciej Patrzyk; Claus-Dieter Heidecke; Tobias Schulze
Journal:  Langenbecks Arch Surg       Date:  2019-11-09       Impact factor: 3.445

2.  Fecal and urinary incontinence are major problems associated with rectal cancer.

Authors:  Leif Schiffmann; Karel Kostev; Matthias Kalder
Journal:  Int J Colorectal Dis       Date:  2019-11-22       Impact factor: 2.571

Review 3.  Management of Lower Urinary Tract Symptoms After Pelvic Radiation in Females.

Authors:  Laura S Leddy
Journal:  Curr Urol Rep       Date:  2018-10-31       Impact factor: 3.092

4.  Urinary dysfunction in women following total mesorectal excision versus partial mesorectal excision for treatment of rectal cancer.

Authors:  Henry H Chill; Shani Y Parnasa; Noam Shussman; Roie Alter; Briggite Helou; Adiel Cohen; Alon J Pikarsky; David Shveiky
Journal:  BMC Womens Health       Date:  2021-06-07       Impact factor: 2.809

5.  Potentially preventable urinary tract infection in patients with type 2 diabetes - A hospital-based study.

Authors:  Maria Cristina Carrondo; Joaquim Jorge Moita
Journal:  Obes Med       Date:  2020-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.